Zentalis Pharmaceuticals, Inc.
ZNTL
$4.10
-$0.06-1.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.14M | 3.77M | 10.78M | 7.30M | 10.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.86M | 34.46M | 33.73M | 34.91M | 36.63M |
| Operating Income | -37.86M | -34.46M | -33.73M | -34.91M | -36.63M |
| Income Before Tax | -35.23M | -34.77M | -26.69M | -26.87M | -48.28M |
| Income Tax Expenses | 120.00K | 442.00K | -- | -- | -- |
| Earnings from Continuing Operations | -35.35M | -35.22M | -26.69M | -26.87M | -48.28M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.35M | -35.22M | -26.69M | -26.87M | -48.28M |
| EBIT | -37.86M | -34.46M | -33.73M | -34.91M | -36.63M |
| EBITDA | -37.70M | -34.30M | -33.57M | -34.75M | -36.37M |
| EPS Basic | -0.50 | -0.49 | -0.37 | -0.37 | -0.67 |
| Normalized Basic EPS | -0.31 | -0.30 | -0.23 | -0.22 | -0.28 |
| EPS Diluted | -0.50 | -0.49 | -0.37 | -0.37 | -0.67 |
| Normalized Diluted EPS | -0.31 | -0.30 | -0.23 | -0.22 | -0.28 |
| Average Basic Shares Outstanding | 70.26M | 71.66M | 72.14M | 71.99M | 71.68M |
| Average Diluted Shares Outstanding | 70.26M | 71.66M | 72.14M | 71.99M | 71.68M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |